BDX

Becton Dickinson and Company

BDX, USA

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

https://www.bd.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
BDX
stock
BDX

Rakuten Investment Management Inc. Acquires Shares of 817,069 Becton, Dickinson and Company $BDX MarketBeat

Read more →
BDX
stock
BDX

Vest Financial LLC Increases Stake in Becton, Dickinson and Company $BDX MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$206.6667

Analyst Picks

Strong Buy

4

Buy

2

Hold

11

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Low

35.59

Low 50

High 10

Price to Book Ratio (P/B)

-

High

2.30

Low 1

High 3

Return on Equity (ROE)

-

Very Low

1.94 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

0.89 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

45.32 %

Low 5%

High 15%

Debt to Equity

-

Very Low

1.18

Low 1

High 0.3

Investors

* Institutions hold a combined 81.33% of the total shares of Becton Dickinson and Company

1.

Vanguard Group Inc

(11.272%)

since

2025/06/30

2.

BlackRock Inc

(9.5175%)

since

2025/06/30

3.

T. Rowe Price Investment Management,Inc.

(5.6444%)

since

2025/06/30

4.

State Street Corp

(4.6797%)

since

2025/06/30

5.

T. Rowe Price Capital Appreciation

(3.6569%)

since

2025/07/31

6.

Vanguard Total Stock Mkt Idx Inv

(3.1405%)

since

2025/07/31

7.

T. Rowe Price Associates, Inc.

(3.0994%)

since

2025/06/30

8.

Arnhold & S. Bleichroeder Advisers, LLC

(3.0654%)

since

2025/06/30

9.

Massachusetts Financial Services Company

(2.9706%)

since

2025/06/30

10.

Vanguard 500 Index Investor

(2.4748%)

since

2025/07/31

11.

Geode Capital Management, LLC

(2.3458%)

since

2025/06/30

12.

First Eagle Global A

(2.3061%)

since

2025/07/31

13.

JPMorgan Chase & Co

(1.5854%)

since

2025/06/30

14.

Morgan Stanley - Brokerage Accounts

(1.3926%)

since

2025/06/30

15.

ClearBridge Advisors, LLC

(1.3323%)

since

2025/06/30

16.

NORGES BANK

(1.3234%)

since

2025/06/30

17.

Fidelity 500 Index

(1.2675%)

since

2025/07/31

18.

SPDR® S&P 500® ETF

(1.2053%)

since

2025/08/31

19.

iShares Core S&P 500 ETF

(1.2032%)

since

2025/08/31

20.

American Century Companies Inc

(1.1919%)

since

2025/06/30

21.

Nordea Investment Mgmt Bank Demark A/s

(1.1742%)

since

2025/06/30

22.

Charles Schwab Investment Management Inc

(1.1312%)

since

2025/06/30

23.

Vanguard Mid Cap Index Institutional

(1.1153%)

since

2025/07/31

24.

Amvescap Plc.

(1.0673%)

since

2025/06/30

25.

Bank of America Corp

(1.0656%)

since

2025/06/30

26.

Harris Associates L.P.

(1.0178%)

since

2025/06/30

27.

Putnam Large Cap Value A

(0.9869%)

since

2025/07/31

28.

Amundi

(0.9744%)

since

2025/06/30

29.

Generation Investment Management LLP

(0.9627%)

since

2025/06/30

30.

Vanguard Value Index Inv

(0.8863%)

since

2025/07/31

31.

JNL/T. Rowe Price Capital Appreciation A

(0.798%)

since

2025/06/30

32.

BlackRock Equity Dividend Instl

(0.7585%)

since

2025/07/31

33.

The Health Care Select Sector SPDR® ETF

(0.6828%)

since

2025/08/31

34.

JPMorgan Equity Income I

(0.6358%)

since

2025/07/31

35.

JPM US Equity Income-Composite

(0.6358%)

since

2025/06/30

36.

Vanguard Institutional Index I

(0.6044%)

since

2025/07/31

37.

T. Rowe Price U.S. Value Equity Tr-D

(0.5624%)

since

2025/06/30

38.

Vanguard Dividend Appreciation ETF

(0.5408%)

since

2025/07/31

39.

State St S&P 500® Indx SL Cl III

(0.5337%)

since

2025/08/31

40.

Franklin Rising Dividends A

(0.5195%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

3.24

Latest Release

Date

2025-09-30

EPS Actual

3.96

EPS Estimate

3.92

EPS Difference

0.04

Surprise Percent

1.0204%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(6.5)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.